首页> 外文期刊>Case Reports & Clinical Practice Review >Durable Response of Leptomeningeal Metastasis of Breast Cancer to Salvage Intrathecal Etoposide After Methotrexate: A Case Report and Literature Review
【24h】

Durable Response of Leptomeningeal Metastasis of Breast Cancer to Salvage Intrathecal Etoposide After Methotrexate: A Case Report and Literature Review

机译:甲氨蝶呤治疗乳腺癌前脑膜转移对鞘内注射依托泊苷的持久反应:一例病例并文献复习

获取原文
获取外文期刊封面目录资料

摘要

BACKGROUND : Leptomeningeal metastasis (LM) is recently on the rise as one of important clinical issues in the management of metastatic breast cancer (MBC). Clinical research on salvage intrathecal chemotherapy after failure of first-line treatment for MBC patients with LM has rarely been reported.CASE REPORT : We report the case of a breast cancer patient with LM who showed durable response to salvage intrathecal etoposide subsequent to failure of methotrexate. Etoposide 1 mg was injected through an Ommaya reservoir every week. Corticosteroid was used for a prophylaxis of chemical arachnoiditis. The treatment was successful palliation of LM for 33 weeks without significant adverse effects. Time to neurologic progression was estimated to be about 230 days for the treatment and overall survival was 301 days from the diagnosis of LM.CONCLUSIONS : Intrathecal etoposide can be considered as an additional treatment option for LM in breast cancer. Further large clinical studies are necessary to investigate the effectiveness and safety of the treatment.
机译:背景:近端脑膜转移瘤(LM)作为转移性乳腺癌(MBC)处理中的重要临床问题之一,正在兴起。很少有针对MBC LM患者一线治疗失败后进行挽救性鞘内化疗的临床研究。病例报告:我们报道了LM乳腺癌患者对鞘内注射依托泊苷的持久治疗甲氨蝶呤的失败。每周通过Ommaya水库注射1毫克依托泊苷。皮质类固醇用于预防化学蛛网膜炎。该疗法成功缓解了LM 33周,无明显不良反应。据估计,从治疗LM到达到神经病学进展的时间约为230天,从LM诊断出的总生存期为301天。结论:鞘内注射依托泊苷可以被认为是乳腺癌LM的另一种治疗选择。为了研究治疗的有效性和安全性,还需要进行进一步的大型临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号